A Caspase Inhibitor in Chronic Hepatitis C (HCV) Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

204

Participants

Timeline

Start Date

July 31, 2004

Primary Completion Date

October 31, 2005

Study Completion Date

October 31, 2005

Conditions
Hepatitis C, Chronic
Interventions
DRUG

IDN-6556

DRUG

Placebo

Trial Locations (15)

10029

Mt. Sinai School of Medicine, New York

23298

Medical College of Virginia, Richmond

27599

University of North Carolina, Chapel Hill

27715

Duke University Medical Center, Durham

33136

University of Miami, Miami

44109

Metrohealth Medical Center, Cleveland

45267

University of Cincinnati, Cincinnati

46202

Indiana University School of Medicine, Indianapolis

48202

Henry Ford Hospital, Detroit

55905

The Mayo Clinic, Rochester

85054

Mayo Clinic Hospital, Phoenix

92067

Scripps Clinic, La Jolla

94115

California Pacific Medical Center, San Francisco

94143

University of California, San Francisco, San Francisco

02215

Beth Israel Deaconness Medical Center, Boston

Sponsors
All Listed Sponsors
collaborator

Idun Pharmaceuticals

INDUSTRY

lead

Conatus Pharmaceuticals Inc.

INDUSTRY

NCT00088140 - A Caspase Inhibitor in Chronic Hepatitis C (HCV) Patients | Biotech Hunter | Biotech Hunter